+116.0%
SLV vs MRNA
+221.0%
-105.0%
-58.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.2% | -3.4% | +1.3% | -2.0% |
| 7D | -5.8% | -12.1% | +6.3% | -5.2% |
| 30D | -12.1% | -1.3% | -10.8% | -12.1% |
| 3M | -24.1% | +250.9% | -275.1% | -31.8% |
| 6M | -44.4% | +343.0% | -387.4% | -51.6% |
| YTD | -31.5% | +657.4% | -688.9% | -42.8% |
| 1Y | -6.9% | +794.9% | -801.8% | -23.3% |
| 3Y | +116.0% | +218.1% | -102.1% | +71.9% |
| All | +116.0% | +221.0% | -105.0% | +71.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling